DSIP
⚠️ Structural Separation Notice
The Ageless Pep Academy is a clinical education property independent from any commerce operation. Any references in this profile to Ageless Peps product SKUs, pricing, or the agelesspeps.com domain are for completeness and transparency; they are not endorsements and do not form part of the clinical education content. Clinicians are responsible for independent verification of any product sourcing decision. The Academy's Medical Director provides editorial oversight only and does not endorse commercial products.
Delta Sleep-Inducing Peptide; endogenous nonapeptide that promotes delta-wave (slow-wave) sleep, enhances nocturnal GH secretion, modulates the HPA stress axis, and possesses antioxidant properties without sedative dependency.
Quick Facts
| Property | Value |
|---|---|
| Also Known As | DSIP, Delta Sleep-Inducing Peptide, Deltaran (Russian brand) |
| Category | Sleep / Recovery / Stress Reduction |
| Sequence | Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (9 amino acids) |
| Molecular Weight | 848.9 Da |
| Molecular Formula | C35H48N10O15 |
| PubChem CID | 68816 |
| Administration | SubQ / Intranasal / IV (research) |
| Typical Dose Range | 100-300 mcg SubQ at bedtime |
| Half-Life | ~30 minutes in blood; accumulates in tissues with repeated dosing |
| Storage | Lyophilized -20C long-term; reconstituted 2-8C 1-2 weeks; protect from light |
| FDA Status | Research-only (not approved; available as Deltaran in some countries) |
| WADA Status | Not listed |
Mechanism of Action
DSIP is an endogenous nonapeptide originally isolated from rabbit thalamus by Monnier and colleagues in 1974. It promotes the transition to NREM Stage 3 (delta wave/slow-wave) sleep — the deepest and most physiologically restorative sleep phase — through mechanisms that remain incompletely characterized after decades of research. Unlike conventional sedatives (benzodiazepines, Z-drugs), DSIP promotes physiological sleep architecture without respiratory depression, morning grogginess, or dependency. PMID 16539679
DSIP enhances nocturnal growth hormone secretion by amplifying the GH pulse that naturally occurs during slow-wave sleep, likely through somatostatin reduction at the hypothalamic level. It modulates the hypothalamic-pituitary-adrenal (HPA) axis by reducing ACTH release from the anterior pituitary, subsequently lowering cortisol levels and facilitating both sleep onset and stress reduction. PMID 6548966
Human sleep studies have demonstrated that DSIP produces both acute effects (increased slow-wave sleep on the night of administration) and delayed effects (improved sleep architecture 6-24 hours after administration), suggesting tissue accumulation and sustained neuromodulatory activity beyond its short plasma half-life. PMID 6895513
DSIP modulates stress-related neural circuits, reducing Fos expression (a marker of neuronal activation) in limbic structures including the amygdala and hypothalamus under stress conditions. PMID 22432135
Recent research on DSIP fusion peptides has demonstrated enhanced blood-brain barrier crossing and efficacy in insomnia models, suggesting improved delivery strategies for clinical translation. PMID 39444618
Key Research Areas
- Sleep Architecture: Promotes delta-wave sleep without sedative dependency; both acute and delayed effects documented in human studies. PMID 6895513
- Stress Axis Modulation: Reduces ACTH/cortisol via HPA axis modulation; reduces stress-related limbic activation. PMID 22432135
- Multivariate Neuromodulation: Functions as a "sleep-promoting substance" with effects on pain, stress, temperature, and endocrine regulation. PMID 6548966
- BBB Delivery: Fusion peptide strategies to enhance CNS delivery for insomnia treatment. PMID 39444618
- Mechanism Controversy: Despite decades of research, the precise receptor target and signaling pathway remain "an unresolved riddle." PMID 16539679
Evidence Level Summary
| Evidence Type | Count | Notes |
|---|---|---|
| Human RCTs | 1 | Acute and delayed sleep effects (1983) |
| Human observational | 0 | — |
| Animal in vivo | 2 | Stress-related Fos, fusion peptide insomnia |
| In vitro | 0 | — |
| Systematic reviews | 0 | — |
| Narrative reviews | 2 | Comprehensive reviews of DSIP biology |
Clinical Applications
- Sleep Disorders — Slow-wave sleep enhancement, insomnia
- Anxiety — HPA axis modulation, cortisol reduction
- Anti-Aging — GH pulse enhancement during sleep for tissue repair
Protocols Using This Peptide
- (Sleep optimization stacks; no dedicated vault protocol yet)
Ageless Peps Products
- AP-DSIP-Vial — DSIP 5mg Vial, $35
Dosing Reference
Research Dosing Ranges (from literature)
| Route | Dose Range | Frequency | Duration | Source |
|---|---|---|---|---|
| SubQ | 100-300 mcg | At bedtime | 2-4 week cycles | Practitioner guides |
| SubQ | 100-200 mcg | Evening | 2-3 weeks on / 1 week off | Stress reduction |
| Intranasal | Variable | At bedtime | As needed | Research protocols |
Cycling
5 days on / 2 days off or 2-4 weeks on / 1-2 weeks off. Effects may be cumulative — some report best results after 3-5 consecutive nights. No dependency or tolerance has been reported in decades of use. Administer 30-60 minutes before bedtime.
Contraindications & Safety
- Contraindications: Seizure disorders (GABA-ergic modulation; monitor); concurrent CNS depressants (additive sedation)
- Common side effects: Minimal; occasional mild headache, dizziness; very favorable safety profile with decades of research use
- Drug interactions: Additive sedation with benzodiazepines, opioids, and other CNS depressants; opiate receptor interactions — use cautiously in context of opioid therapy
- Pregnancy/nursing: Insufficient data; avoid
- Special populations: No dependency reported; no specific renal/hepatic adjustments known
Cancer Considerations
LIKELY SAFE — Possible anti-tumor benefit. A preclinical study showed Deltaran (DSIP preparation) decreased spontaneous tumor incidence 2.6-fold in mice, with specific reductions in mammary carcinomas and leukemias (PMID-12782416). DSIP's mechanism (sleep/circadian regulation, stress modulation) does not involve angiogenesis, EMT, or growth factor signaling. This is one of the few vault peptides with preclinical evidence suggesting anti-tumor properties. May be a reasonable option for cancer patients needing sleep support, with oncologist awareness.
Synergistic Combinations
- Ipamorelin + DSIP — GHRP at bedtime for synergistic GH pulse + sleep quality
- Sermorelin + DSIP — GHRH at bedtime complement to DSIP sleep enhancement
- Epitalon + DSIP — Pineal/circadian health and anti-aging sleep stack
- Selank + DSIP — Anxiolytic to reduce pre-sleep cortisol
- BPC-157 + DSIP — Recovery optimization during improved sleep
Related Research
| PMID | Title | Year | Study Type |
|---|---|---|---|
| 16539679 | DSIP: A Still Unresolved Riddle | 2006 | Review |
| 6895513 | DSIP: Acute and Delayed Effects on Human Sleep | 1983 | RCT |
| 6548966 | DSIP: Characterization and Multivariate Functions | 1984 | Review |
| 22432135 | DSIP Modulates Stress-Related Fos in Limbic Structures | 2012 | Animal in vivo |
| 39444618 | DSIP Fusion Peptide BBB Crossing: Insomnia Models | 2024 | Animal in vivo |
References
- PMID 16539679 — Unresolved riddle review
- PMID 6895513 — Human sleep study
- PMID 6548966 — Characterization review
- PMID 22432135 — Stress limbic structures
- PMID 39444618 — Fusion peptide BBB
Related
#peptide #sleep #subq